Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| RXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference | ||
| By: PR Newswire Association LLC. - 19 Sep 2017 | Back to overview list |
|
MARLBOROUGH, Mass., Sept. 19, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that Dr. Gerrit Dispersyn, RXi's Chief Development Officer, will present at Ladenburg Thalmann's 3rd annual Healthcare Conference, in New York City. This conference features presentations from life sciences companies across the biopharmaceutical and medical technology sectors and will be held September 26, 2017 at the Sofitel Hotel in New York City. Logo: http://photos.prnewswire.com/prnh/20130917/NE80755LOGO RXi has developed a proprietary self-delivering RNAi (sd-rxRNA) platform proven to be safe and well tolerated in a clinical setting. The Company's novel compounds have the potential to selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Dr. Dispersyn will present a corporate overview that includes the Company's immuno-oncology, dermatology and ophthalmology programs. Date: Tuesday, September 26 The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com approximately 1 hour following the presentation. About RXi Pharmaceuticals RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the potential to selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology, and cell-based immunotherapy. RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. For additional information, visit the Company's website, www.rxipharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release. Contact RXi Pharmaceuticals Corporation View original content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference-300521798.html SOURCE RXi Pharmaceuticals Corporation 
|
||
|
||
 | Back to overview list | |